High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

(2022) N. Villain et al.   REVUE NEUROLOGIQUE

Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease

(2021) Salvatore Spina et al.   BRAIN

Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment

(2021) Timothy S. Anderson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

“Real world” eligibility for aducanumab

(2021) Marco Canevelli et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

(2021) Bruno Dubois et al.   LANCET NEUROLOGY

Off-label use of aducanumab for cerebral amyloid angiopathy

(2021) Steven M Greenberg et al.   LANCET NEUROLOGY

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

(2021) Sebastian Palmqvist et al.   NATURE MEDICINE

Aducanumab for Alzheimer’s disease: A regulatory perspective

(2021) Robert Nisticò et al.   PHARMACOLOGICAL RESEARCH

Influence of education level on MMSE and MoCA scores of elderly inpatients

(2021) Yehuan Wu et al.   Applied Neuropsychology-Adult

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

(2021) Giovanni B. Frisoni et al.   NATURE REVIEWS NEUROSCIENCE

Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent

(2021) Winston Chiong et al.   NEUROLOGY

Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab

(2021) Lukas Sveikata et al.   STROKE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

(2019) Stéphane Epelbaum et al.   BMJ Open

Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways

(2019) Steven M. Greenberg et al.   Nature Reviews Neurology

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease

(2018) Ron Brookmeyer et al.   Alzheimers & Dementia

Serious hemorrhages after ischemic stroke or TIA – Incidence, mortality, and predictors

(2018) Joachim Ögren et al.   PLoS One

Vers une stratégie nationale de diagnostic des troubles cognitifs. Approche commune du Collège de médecine générale et des spécialistes des troubles neurocognitifs

(2018) Pierre Krolak-Salmon et al.   PRESSE MEDICALE

Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

(2018) H. Robert Brashear et al.   JOURNAL OF ALZHEIMERS DISEASE

Is the Folstein's Mini-Mental Test an Aphasia Test?

(2012) Nora Silvana Vigliecca et al.   Applied Neuropsychology-Adult

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease

(2011) Bradley T. Hyman   ARCHIVES OF NEUROLOGY